Lung Transplant for Pulmonary Fibrosis: When Is It Considered?

Pulmonary fibrosis causes permanent scarring of the lung tissue, making it increasingly difficult for the lungs to transfer oxygen and support normal breathing. 

Some forms of pulmonary fibrosis remain relatively stable for years, while others progressively worsen despite appropriate treatment.

When fibrosis becomes advanced and continues to affect breathing, exercise capacity, oxygen levels, and everyday life, a lung transplant may be considered. The decision is not based on a single test.

Why Can Pulmonary Fibrosis Lead to Lung Transplantation?

In pulmonary fibrosis, scar tissue replaces healthy lung tissue. As the scarring progresses, the lungs become less able to expand normally and transfer oxygen into the bloodstream.

Medicines, supplemental oxygen, pulmonary rehabilitation, and other supportive treatments may help manage the condition. 

For some forms of pulmonary fibrosis, antifibrotic treatment can also slow the rate of lung function decline. However, these treatments cannot restore lung tissue that has already been permanently scarred.

When lung damage becomes severe and the disease continues to progress, transplantation may become an option for appropriately selected patients.

When Is Lung Transplant Referral Considered in Pulmonary Fibrosis?

Referral to a transplant centre can happen before a patient reaches end-stage respiratory failure. In fact, early referral is important because pulmonary fibrosis can progress unpredictably, and transplant evaluation itself can take time.

Current international transplant guidance recommends considering referral for people with pulmonary fibrosis when there is evidence of significant disease or progression. Important factors include:

• Reduced lung function, such as a forced vital capacity (FVC) below 80% of the predicted value or a diffusion capacity (DLCO) below 40%
• A significant decline in FVC or DLCO over time
• Increasing breathlessness or functional limitation
• A need for supplemental oxygen, either at rest or during exercise
• Progression visible on chest imaging
• Worsening disease despite appropriate treatment
• Hospitalisation because of respiratory deterioration or an acute exacerbation
• Development of pulmonary hypertension or other complications associated with advanced disease

These factors are used to identify people who may benefit from specialist transplant assessment. They do not mean that every patient meeting one criterion will automatically be listed for transplantation.

How Does Lung Function Affect the Decision?

Pulmonary function tests are an important part of monitoring pulmonary fibrosis. Two measurements are particularly useful: FVC and DLCO.

Forced vital capacity (FVC)

FVC measures the amount of air a person can forcefully breathe out after taking a deep breath. In pulmonary fibrosis, increasing scarring can cause lung volumes to decrease.

A continuing decline in FVC can therefore indicate that the disease is progressing. The rate of decline can sometimes be more informative than a single measurement because it shows how quickly lung function is being lost.

Diffusing capacity (DLCO)

DLCO estimates how effectively gases, particularly oxygen, can move from the lungs into the bloodstream. A reduced or declining DLCO can reflect worsening impairment in gas exchange. Doctors consider it alongside FVC, symptoms, oxygen requirements, exercise capacity, and other findings rather than using it in isolation.

Why Does the Rate of Decline Matter?

Pulmonary fibrosis does not progress at the same speed in every person. Someone whose lung function has remained stable may be managed differently from someone whose lung function is falling rapidly.

A significant decline in lung function over a relatively short period can indicate a higher-risk disease course. Current transplant guidance identifies changes in FVC and DLCO over time as important factors when considering referral and, later, listing.

For example, a relative decline in FVC of around 10% or a relative decline in DLCO of around 15% over two years can support referral. A smaller decline in FVC accompanied by worsening symptoms or radiographic progression can also be significant.

These measurements are not intended to function as a self-assessment tool. The transplant team interprets them in the context of the patient's complete clinical picture.

What Role Does Supplemental Oxygen Play?

As pulmonary fibrosis progresses, oxygen levels may fall, particularly during physical activity. Some patients eventually require supplemental oxygen while walking, sleeping, or even at rest.

Needing oxygen does not automatically mean that a transplant is required. However, an increasing oxygen requirement can be an important sign of advanced disease and is one of the factors that may prompt transplant referral.

Oxygen needs can also provide useful information about how the disease is affecting the lungs during everyday activities, particularly when resting oxygen levels appear relatively preserved.

What About Breathlessness and Reduced Exercise Capacity?

Symptoms are an important part of assessing pulmonary fibrosis. Increasing breathlessness may initially occur only during strenuous activity but can gradually appear with ordinary activities such as walking, bathing, dressing, or climbing stairs.

Doctors may assess exercise capacity using tests such as the six-minute walk test. During this assessment, walking distance and changes in oxygen levels can provide information about how the lungs respond to physical activity.

Significant oxygen desaturation during exercise or a substantial decline in walking distance over time can be important when considering the progression of pulmonary fibrosis and the need for transplant assessment.

What If Pulmonary Fibrosis Suddenly Gets Worse?

Some people with pulmonary fibrosis experience periods of sudden respiratory deterioration or an acute exacerbation. Hospitalisation because of respiratory decline, acute exacerbation, or complications such as pneumothorax can indicate a change in the severity of the disease.

Such events may lead doctors to reconsider the timing of transplant evaluation or listing, particularly when the underlying lung disease was already advanced. This is one reason why transplant discussions should not necessarily be postponed until a severe respiratory crisis occurs.

Does the Type of Pulmonary Fibrosis Matter?

Yes. Pulmonary fibrosis is not one single disease. It can occur as idiopathic pulmonary fibrosis (IPF), connective-tissue-disease-associated interstitial lung disease, chronic hypersensitivity pneumonitis, familial pulmonary fibrosis, and several other conditions.

The underlying diagnosis, pattern of fibrosis, rate of progression, response to treatment, and involvement of other organs can all affect the timing of transplant referral.

For example, people with connective tissue disease or familial pulmonary fibrosis may benefit from earlier specialist assessment because problems outside the lungs can also influence transplant planning.

Does Everyone With Pulmonary Fibrosis Need a Lung Transplant?

No. Many people with pulmonary fibrosis are managed for years without transplantation. The possibility of transplant generally becomes more relevant when the disease is advanced, progressive, and associated with a significant risk of respiratory deterioration despite appropriate treatment.

Some patients may be referred early and monitored for changes while continuing their current treatment. Others may eventually undergo a full transplant evaluation if their disease progresses to a level where transplantation could provide a meaningful benefit.

When Does Referral Become Listing?

Referral and listing are different stages. A patient may be referred to a transplant centre because their pulmonary fibrosis has characteristics associated with progression or poor prognosis. The transplant team then performs a detailed assessment to determine whether transplantation is appropriate.

Listing may be considered later when disease progression and the expected risks of remaining without transplantation become significant enough to justify placement on the waiting list.

Factors that may support consideration of listing in advanced pulmonary fibrosis include substantial declines in FVC or DLCO, significant oxygen desaturation during a six-minute walk test, pulmonary hypertension, or hospitalisation for respiratory deterioration, pneumothorax, or acute exacerbation.

Why Should Transplant Evaluation Begin Before Severe Respiratory Failure?

One of the most important reasons for early referral is that transplant assessment takes time. Patients may need several investigations, consultations, optimisation of their health, rehabilitation, and evaluation of other medical conditions before a final decision is made.

Early assessment also gives patients and families an opportunity to understand the transplant process while the person may still be physically strong enough to undergo evaluation and rehabilitation.

For pulmonary fibrosis, this is particularly relevant because the future course of the disease can be difficult to predict accurately in an individual patient.

The Bottom Line

Lung transplantation may be considered when pulmonary fibrosis becomes advanced, continues to progress, and significantly affects breathing, oxygen levels, exercise capacity, or overall health despite appropriate treatment.

There is no single number that determines when a transplant is needed. Declining FVC or DLCO, increasing oxygen requirements, worsening symptoms, reduced exercise capacity, changes on CT scans, pulmonary hypertension, and respiratory hospitalisations can all contribute to the decision.

For this reason, transplant referral is often considered before severe respiratory failure develops. Early evaluation does not mean that transplantation has to happen immediately. Instead, it allows the transplant team to assess the disease, monitor its progression, address potentially modifiable risks, and determine the appropriate timing if transplantation becomes necessary.